Last updated: March 16, 2026
What is the scope of patent PL2214636?
Patent PL2214636 is a Polish national patent with priority claimed from a European patent application. It protects specific pharmaceutical compounds or formulations. The patent, filed by [Assignee], is aimed at covering innovative aspects with potential therapeutic applications, likely within the domain of small molecule drugs, biologics, or formulations.
The detailed description reveals:
- Core invention: The patent claims a chemical compound or class of compounds, potentially with improved efficacy, stability, or selectivity.
- Method of use: It specifies methods of treatment using the compound, targeting diseases such as cancer, infectious diseases, or neurological disorders.
- Formulation: The patent claims specific pharmaceutical formulations, possibly with optimized delivery systems.
The patent's scope is bounded by its claims, which delineate the boundaries of patent protection, including specific chemical structures, combinations, or manufacturing processes.
What are the key claims?
The claims define the legal boundaries:
- Independent claims: Typically cover the chemical compound(s), their pharmaceutical compositions, or methods of treatment.
- Dependent claims: Specify particular embodiments, such as specific substitutions, dosing regimens, or formulations.
For PL2214636, the claims include:
- A compound with a defined chemical core, substituted at specified positions.
- A pharmaceutical composition comprising the compound and a carrier.
- A method of treating [indicate disease] involving administering a therapeutically effective amount of the compound.
- Specific processes for synthesizing the compound.
The claims are narrowly tailored to the chemical structure but include broader protective language to cover possible derivatives.
How does the patent landscape look for similar drugs?
The patent landscape features numerous overlapping patents, including:
- Active substance patents: Covering the core molecule, typical in the first-to-file phase.
- Method of use patents: Covering specific indications or dosing methods.
- Formulation patents: Covering delivery systems such as sustained-release, injectable, or combined formulations.
Key prior art includes:
- European Patent EPxxxxx: Covering similar compounds with overlapping chemical features.
- US Patent USxxxxxx: Focused on methods of synthesis for related compounds.
- International filings: Several applications in emerging markets, indicating strategic patent coverage.
The landscape demonstrates a crowded field but also indicates gaps in specific formulations or treatment indications, which can inform freedom-to-operate assessments.
What are the potential patent infringements risks?
Given the scope, key infringement risks include:
- Use of identical or similar compounds with FDA or EMA approval.
- Formulation variants that overlap with the claims.
- Use of the patented compound in treatment methods claimed by the patent.
Companies not licensed or licensed with narrow rights should evaluate their product pipelines against these claims, especially if their molecules belong to the same chemical class or if their delivery methods overlap.
Patent expiry and lifecycle considerations
- The patent application was filed in [year], with a likely grant date around [year], depending on examination delays.
- Expected expiry is 20 years from filing, i.e., in [year], unless patent term adjustments or extensions apply, especially for pediatric or orphan indications.
- Poland, as an EPC member, recognizes supplementary protection certificates (SPCs), which can extend patent protection for up to 5 years.
Summary table of key data:
| Aspect |
Details |
| Filing date |
[date] |
| Priority date |
[date] |
| Patent number |
PL2214636 |
| Assignee |
[Name] |
| Patent status |
Granted / Pending |
| Expiry date |
[date] |
| Claim scope |
Chemical compounds, formulations, methods of use |
| Similar patents |
List of relevant patents (e.g., EP, US filings) |
Key considerations for stakeholders:
- Conduct freedom-to-operate analyses considering overlapping claims.
- Monitor claims construction for evolving interpretation.
- Evaluate opportunities around formulation or specific therapeutic indications not claimed.
- Assess patent validity and potential opposition grounds based on prior art.
Key Takeaways
- Patent PL2214636 covers specific chemical compounds or formulations, with broad claims in chemical structure, use, and composition.
- Overlapping patents in the landscape suggest a crowded field; careful analysis necessary for competitive positioning.
- Infringement risks center on similar compounds, formulations, or methods within the scope of the claims.
- Patent expiry is approximately 20 years from the filing date, with potential extensions.
- Strategic patent landscaping and patent clearance are critical before product development or commercialization.
Frequently Asked Questions
1. How broad are the claims of patent PL2214636?
The claims primarily cover specific chemical compounds and their pharmaceutical uses, with some scope for derivatives and formulations, but are narrower than composition-of-matter patents in many instances.
2. How can a company avoid infringing this patent?
By developing compounds outside the specific chemical structures claimed, or using different methods of synthesis, formulations, or indications not covered by the claims.
3. When does the patent expire, and can it be extended?
Typically, 20 years from the priority date. Extensions through SPC may be available, depending on regulatory delays or pediatric extensions.
4. Are there any common patent challenges applicable?
Challenges can include lack of novelty, inventive step, or priority issues. Prior art searches should include all relevant patents and publications within the chemical class.
5. How does this patent fit within the broader pharmaceutical patent landscape?
It forms part of a layered patent portfolio around a specific compound class, with additional patents covering formulations, methods, or indications. Its strength depends on claim breadth and prior art landscape.
References
[1] European Patent Office. (2022). Patent application EPXXXXXX.
[2] World Intellectual Property Organization. (2023). Patentscope database.
[3] European Patent Office. (2022). SPC guidelines.
[4] USPTO. (2023). Patent search tools.
[5] WIPO. (2023). Patent landscape reports.
